Also, in Module II, we identified two mutations in BRCA1, one mutation in BRCA2, one mutation in PALB2, three mutations in ATM, and one mutation in NBN in the patients who qualified for molecular testing for Lynch syndrome (and failed to meet either the criteria of the HBOC or the inclusion criteria for Module I). This evidence concerns the gene ATM and Lynch syndrome.